|
|
|
| Discussion on the mechanism of Shema Oral Liquid in the treatment of Coronavirus disease 2019 based on network pharmacology |
| FENG Jihong1 TAN Wangxiao2 ZHANG Shuo1 JIN Shiyuan3 BI Mingda2 QIN Yunpu2 ZHAO Kun4 |
1.Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China; 2.Chinese Medicine Research Institute, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China;
3.Beijing Health School, Beijing 100053, China;
4.Hainan Zhongsheng Hemei Biopharmaceutical Co., Ltd., Hainan Province, Haikou 570100, China |
|
|
|
Abstract Objective To investigate the mechanism of Shema Oral Liquid in the treatment of Coronavirus disease 2019 (COVID-19). Methods The active components and targets of Shema Oral Liquid were searched by Chinese medicine pharmacology database and analysis platform (TCMSP). COVID-19 related targets were obtained from GeneCards database. The potential targets of Shema Oral Liquid in the treatment of COVID-19 were obtained by mapping the drug targets and disease targets for subsequent analysis. Protein-protein interaction (PPI) network and drug-component-target-disease network were constructed by STRING database and Cytoscape software, and disease and function analysis were carried out through Ingenuity Pathway Analysis (IPA). The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was carried out by using STRING database. Results A total of 106 active components and 53 potential therapeutic targets of COVID-19 from 10 traditional Chinese medicines in Shema Oral Liquid were screened. The main active components included quercetin, luteolin, β-sitosterol, kaempferol, stigmasterol, etc., and the key targets involved MAPK3, TNF, IL-6, MAPK8, CXCL8, etc. The 53 therapeutic targets were mainly involved in cell death and survival, body injury and abnormality, inflammatory response and other biological functions. KEGG pathway enrichment resulted in 169 biological pathways, mainly involving IL-17, Toll-like receptor, HIF-1, TNF signaling pathways, etc. Conclusion Shema Oral Liquid may act on IL-6, TNF, MAPK8, CXCL8 and other targets through various active ingredients such as quercetin, luteolin, β-sitosterol, kaempferol, and then regulate multiple pathways such as IL-17, TNF, Toll-like receptor, and HIF-1 to treat COVID-19.
|
|
|
|
|
|
[1] 中华预防医学会新型冠状病毒肺炎防控专家组.新型冠状病毒肺炎流行病学特征的最新认识[J/OL].中国病毒病杂志. https：//doi.org/10.16505/j.2095-0136.2020.0015.
[2] 中国-世界卫生组织新型冠状病毒肺炎（COVID-19）联合考察报告[EB/OL].疾病预防控制局，2020-02-29 [2020-04-12]. http：//www.nhc.gov.cn/jkj/s3578/202002/87fd9251 0d094e4b9bad597608f5cc2c.shtml.
[3] 中华人民共和国国务院新闻办公室.国新办举行中医药防治新冠肺炎重要作用及有效药物发布会[EB/OL].湖北：国务院新闻办公室， （2020-03-23）[2020-04-12]. http：//www.scio.gov.cn/xwfbh/xwbfbh/wqfbh/42311/42768/wz42770/Document/1675777/1675777.htm?flag=1.
[4] 李芹，陈志斌.福建省新型冠状病毒肺炎中医诊疗专家共识[J].福建中医药，2020，51（2）：8-10.
[5] 北京市新型冠状病毒肺炎中医药防治方案（试行第四版）[J/OL].北京中医药：1-7. [2020-04-09]. http：//kns.cnki.net/kcms/detail/11.5635.R.20200316.1713.004.html.
[6] 姚运秀，贺桢翔，刘晓凤，等.基于网络药理学和分子对接技术的抗病毒颗粒治疗新型冠状病毒肺炎（COVID-19）的潜在物质基础研究[J/OL].中草药. http：//kns.cnki.net/kcms/detail/12.1108.R.20200302.0849.002.html.
[7] 龚普阳，郭瑜婕，李晓朋，等.基于网络药理学与分子对接技术的金花清感颗粒防治新型冠状病毒肺炎的潜在药效物质研究[J/OL].中草药. http：//kns.cnki.net/kcms/detail/12.1108.R.20200326.1115.002.html.
[8] 刘萍，唐富山，朱艳，等.槲皮素对PM 2.5导致支气管上皮细胞炎症的保护作用[J].中药药理与临床，2017，33（1）：22-26.
[9] Zhang X，Cai Y，Zhang W，et al. Quercetin ameliorates pulmonary fibrosis by inhibiting SphK1/S1P signaling [J]. Biochem Cell Biol，2018，96（6）：742-751.
[10] 李海波，于洋，王振中，等.热毒宁注射液抗病毒活性成分研究（Ⅰ）[J].中草药，2014，45（12）：1682-1688.
[11] Liu X，Meng J. Luteolin alleviates LPS-induced bronchopneumonia injury in vitro and in vivo by down-regulating microRNA-132 expression [J]. Biomed Pharmacother，2018，106：1641-1649.
[12] Yu WY，Li L，Wu F，et al. Moslea Herba flavonoids alleviated influenza A virus-induced pulmonary endothelial barrier disruption via suppressing NOX4/NF-kappaB/MLCK pathway [J]. J Ethnopharmacol，2020，253：112641.
[13] Zhi H，Jin X，Zhu H，et al. Exploring the effective materials of flavonoids-enriched extract from Scutellaria baicalensis roots based on the metabolic activation in influenza A virus induced acute lung injury [J]. J Pharm Biomed Anal，2020，177：112876.
[14] 杨晨茜，瞿娇，刘怡彤，等.新型冠状病毒肺炎的免疫失衡及干预策略[J].中国药理学通报，2020，4：445-453.
[15] Huang C，Wang Y，Li X，et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan，China [J]. Lancet，2020，395（10223）：497-506.
[16] Zhou YG，Fu BQ，Zheng XH，et al. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus [J]. BioRxiv. doi：https：//doi.org/10.1101/2020. 02.12.945576.
[17] Wan SX，Yi QJ，Fan SB，et al. Characteristics of lymphocyte subsets and cytokines inperipheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia（NCP）[J/OL]. MedRxiv，2020. doi：10.1101/2020. 02.10.20021832.
[18] 中华人民共和国国家卫生健康委员会办公厅,国家中医药管理局办公室.新型冠状病毒肺炎诊疗方案(试行第七版)[J].中国医药，2020，15（6）：801-805.
[19] Kawaguchi M，Adachi M，Oda N，et al. IL-17 cytokine family [J]. J Allergy Clin Immunol，2004，114（6）：1265-1273.
[20] Ding Q，Liu GQ，Zeng YY，et al. Role of IL-17 in LPS-induced acute lung injury：an in vivo study [J]. Oncotarget，2017，8（55）：93704-93711.
[21] Cauvi DM，Williams MR，Bermudez JA，et al. Elevated expression of IL-23/IL-17 pathway-related mediators correlates with exacerbation of pulmonary inflammation during polymicrobial sepsis [J]. Shock，2014，42（3）：246-255.
[22] Probert，L. TNF and its receptors in the CNS：The essential，the desirable and the deleterious effects [J]. Neuroscience，2015，302：2-22.
[23] McDermott JE. Mitchell HD，Gralinski LE，et al. The effect of inhibition of PP1 and TNFalpha signaling on pathogenesis of SARS coronavirus [J]. BMC Syst Biol，2016，10（1）：93.
[24] Wong JP，Christopher ME，Viswanathan S，et al. Activation of toll-like receptor signaling pathway for protection against influenza virus infection [J]. Vaccine，2009，27（25/26）：3481-3483.
[25] Semenza GL. Oxygen sensing，hypoxia-inducible factors，and disease pathophysiology [J]. Annu Rev Pathol，2014， 9：47-71.
[26] Fu X，Zhang F. Role of the HIF-1 signaling pathway in chronic obstructive pulmonary disease [J]. Exp Ther Med，2018，16（6）：4553-4561. |
|
|
|
